Summary The kinetics of dexamethasone-induced death of CCRF CEM clone C7A human lymphoblastic leukaemia cells was determined with respect to changes in the expression of the c-myc protein. Cell death was characterised as being by apoptosis: cells with an intact plasma membrane had condensed chromatin and were characterised as having approximately 300 kbp fragments when DNA integrity was analysed by pulsed-field electrophoresis. Onset of apoptosis required a minimum of 36 h exposure to 5 AIM dexamethasone; before this time no apoptotic cells were observed. This 36 h incubation period appeared to be necessary to prime the cells for subsequent death by apoptosis. In the continued presence of dexamethasone the percentage of apoptotic cells increased to 60% apoptotic cells by 54 h. Investigation of changes in c-myc protein showed that it was undetectable after 12 h of incubation with dexamethasone, although cells were not committed to die at this time. Cells were treated with dexamethasone for 54 h and for various pulsed periods with a non-toxic concentration of cycloheximide (200 nM) . When cycloheximide was present during the first 36 h priming period of dexamethasone treatment, there was an immediate loss of c-myc protein and apoptosis at 54 h was completely inhibited. In contrast, there was no inhibition of apoptosis when dexamethasone-treated cells were incubated with an 18 h pulse of cycloheximide added after 36 h. Cells exposed to dexamethasone for 36 h ('primed') were given various periods of dexamethasone-free incubation before readdition of dexamethasone for a further 18 h. The longer the cells were free of drug after priming, the less susceptible they became to apoptosis, suggesting a slow decay of their 'memory' of the initial 36 h period of exposure. Cycloheximide inhibited the decay of this memory. Removal of dexamethasone after a 36 h exposure was characterised by a subsequent 24 h suppression of c-myc protein expression. Despite this, 90% of cells became refractory to apoptosis before the reappearance of c-myc protein. The evidence does not support the hypothesis that changes in c-myc expression are required for the engagement of apoptosis of CEM cells.
The induction of apoptosis in lymphocytes and lymphoblastoid leukaemic cell lines by glucocorticoids provides a useful model for the study of the changes in gene expression that may initiate their demise (Owens & Cohen, 1992) . In the human T-lymphocytic cell line CCRF CEM, evidence to date suggests that suppression of gene expression is required for the initiation of apoptosis (Yuh & Thompson, 1989; Nazareth et al., 1991) . Congruent with the idea that transcriptional suppression is required, Yuh & Thompson (1989) reported that an early event in the dexamethasone-induced cell death of CCRF CEM clone C7A cells was a decrease in the transcription of the c-myc oncogene, itself postulated to be a transcriptional regulator (Cole, 1991; Eilers et al., 1991) . Although levels of cellular c-myc RNA fell by 12 h, the cells did not die at this time but required another 24 h of dexamethasone exposure before cell death was observed (Yuh & Thompson, 1989) . Recently, it was reported that transient transfection of these cells with a number of c-myc constructs inhibited dexamethasone-induced apoptosis (Thulasi et al., 1993) . This finding contrasts with recent findings that deregulated expression of c-myc in mesenchymal and myeloid cells is a potent inducer of apoptosis (Askew et al., 1991; Evan et al., 1992) . Furthermore, the hypothesis that transcriptional suppression by dexamethasone is required to initiate a programmed cell death, and specifically the c-myc gene, had to be reconciled with the finding that CCRF CEM apoptotic cell death was partially inhibited by cycloheximide, an inhibitor of protein synthesis (Bansal et al., 1991 Norman & Thompson (1977) and described further by Yuh & Thompson (1989 Ltd., 1994 were dissolved in absolute ethanol,'the final volume of which was not greater than 0.1% (v/v) . Control cultures received the solvent alone. All experiments were repeated at least three times.
Measurement of cell integrity and apoptosis Cell membrane integrity was measured by the exclusion of a 0.4% solution of trypan blue. Apoptosis was measured by addition (1:1) of a solution of 10 ig ml' acridine orange (Molecular Probes, Eugene, OR, USA) to suspensions of between 105 and 106 cells ml1'. Apoptotic cells were scored as described previously; these had condensed chromatin but an intact plasma membrane that excluded trypan blue (Dive et al., 1992 ) (see Figure 1) low melting point agarose prepared in PBS, and set into plugs using a Perspex mould. The plugs were incubated at 50°C for 24 h in 1 ml of L buffer (0.1 M EDTA pH 8.0, 0.01 M Tris-Cl pH 7.6, 0.02 M sodium chloride) containing 1 mg ml-' proteinase K. The plugs were washed twice for 2 h in L buffer. Prior to electrophoresis the plugs were equilibrated in TE (10 mM Tris EDTA, pH 8.0). The plugs were sealed into a 1.5%. gel with 1% low melting point agarose.
Lambda phage and yeast artificial chromosome fragments were used as markers ranging from 50 to 1,000 kb. The electrophoresis was performed for 24 h at 150 V in 0.5 x TAE (40 mM Tris acetate, 1 mM EDTA, pH 8.6) with a pulse time of 65 s using a Walter II horizontal gel chamber (Tribotics). The gel was stained with ethidium bromide and viewed under ultraviolet light.
Western blotting Proteins from 1 x 105 cells were separated using SDS-PAGE and electrophoretically transferred to nitrocellulose filter (Hybond Extra-C, Amersham, UK) by the method of Tobin et al. (1979) . Immunoblotting was performed using the monoclonal mouse anti-human antibody, CT9, raised to a peptide from the C-terminal end of the c-myc protein (Evan et al., 1985) . Peroxidase-conjugated secondary antibodies were incubated with the blots for 1 h before visualising the proteins by use of an enhanced chemoluminescence system, according to the manufacturer's instructions (Amersham, UK). Gels were then stained with Coomassie blue to ensure that transfer was complete. 2.5mgml-l propidium iodide for 1-2min prior to flow cytometric analysis using a Coulter Epics V (Coulter, Luton, UK). The cytometer was set to excite at 400 mW with the 488 nm line; red fluorescence was collected through a 630-nm-long bandpass filter. Approximately 2 x 104 cells were analysed with respect to red fluorescence, at a flow rate of between 2 and 2.5 x 103 cells s-'. Data were analysed as single-parameter DNA frequency histograms using in-house computer software.
Results
Morphological and biochemicalfeatures of CCRF CEM clone C7A cell apoptosis Figure la shows the morphological features of 5 jtM dexamethasone-induced apoptosis in clone C7A cells. Typically, fluorescence microscopy showed that apoptotic cells contained discrete masses of condensed chromatin while membrane integrity was maintained at >95% as measured by the exclusion of trypan blue. With time, membrane integrity was lost and the cells then appeared to be swollen and necrotic. Morphological analysis allowed quantitative kinetic estimations of the rate of onset of apoptosis; this type of analysis has been absent from other studies, in which cell lysis and loss of membrane integrity have been estimated. In our hands, the loss of membrane integrity was an event occurring after the appearance of condensed chromatin. When the numbers of plasma membrane-intact cells with morphological features of chromatin condensation was maximum (>80%), isolation of DNA from these cells showed that it had undergone a modest degree of internucleosomal cleavage typical of apoptosis, presumably after activation of an endonuclease (Figure lb) . Despite intensive efforts only a very weak 'chromatin ladder' typical of the internucleosomal cleavage of DNA to 180-200 bp fragments was observed. However, pulsed-field electrophoresis, which allows the resolution of larger fragments of DNA, showed the early appearance of approximately 300 kbp DNA fragments at times corresponding to the appearance of condensed chromatin (Figure 1c ), although this was accompanied by a general fragmentation to lower molecular weights. The loss of the 300 kbp fragment with time and the increase in intensity of the smaller fragments was an event similar to that observed by us in mesenchymal and epithelial cells undergoing apoptosis (Oberhammer et al., 1993) and in thymocytes (Brown et al., 1993) . This is discussed below. 21.5% to 78% at 48 h and by 25.6% to 82% by 54 h. Hypodiploid material, representing apoptotic cells, was gated out from each of these analyses.
Kinetics of dexamethasone-induced apoptosis
Changes in the expression of c-myc protein The changes in cellular levels of the c-myc protein during incubation with dexamethasone are shown in Figure 2c and are in good agreement with the estimation of changes in the cellular amount of c-myc RNA, which fell dramatically after 12 h, as also reported by Yuh & Thompson (1989) under almost identical conditions, but using 1 gM dexamethasone. The rapid disappearance of protein reflects the very short half-life of the c-myc protein (c. 0.5 h) (Waters et al., 1991) .
Inhibition of apoptosis and reduction of c-myc protein by cycloheximide Cycloheximide (CHX) (178 nM) has been shown to partially inhibit glucocorticoid-induced apoptosis in CCRF CEM cells (Bansal et al., 1991) . At concentrations > 1 lLM we found it to induce significant (> 50% by 48 h) apoptosis, as has been reported by others (Collins et al., 1991) . We found that concentrations less than 1 ,IM for 48 h did not induce apoptosis. Using pulsed exposures to cycloheximide, we attempted to determine whether there are times during the first 36 h of dexamethasone treatment, and thereafter, during which cells are sensitive to the effects of an inhibitor of protein synthesis.
We also wondered what effect cycloheximide would have on changes in the c-myc protein content of the cells. There was a profound inhibition of apoptosis when CHX was present during the whole of first 36 h 'priming' period of exposure to dexamethasone (Figure 3 ). Treatment with cycloheximide during the period after c-myc protein had become undetectable (from 18 to 54 h) significantly inhibited apoptosis. Most interestingly, incubation with CHX after the initial 36 h exposure to dexamethasone, i.e. at a time when the cells were 'primed' for apoptosis, had no effect on the amount of apoptosis observed at 54 h. It should be noted that during this cycloheximide-insensitive period, there was a continued requirement for dexamethasone (see Figure 2 ). (Figure 2 ). The ability of the cells to undergo apoptosis declined as the period of drug-free exposure after 'priming' was extended ( Figure 5a ). Thus, the dexamethasone-treated cells lost the 'memory' of their initial 36 h exposure to dexamethasone. We were particularly interested in the kinetics of the reappearance of the c-myc protein in comparison with this time-dependent fall in the susceptibility of the cells to apoptosis as memory of the 'priming' events was lost. Figure 5b shows that c-myc protein was not detectable by Western blotting until 24 h, by which time >50% the total cell population had already-become resistant to the induction of apoptosis on readdition of dexamethasone. Most pertinently, after 12 h of a drug-free incubation and subsequent readdition of dexamethasone, apoptosis had fallen from 60% to 20%, although no c-myc protein was detectable at 12 h. Interestingly, incubation with CHX during the drug-free period maintained some of the sensitivity of the cells to subsequent readdition of dexamethasone for 18 h ( Figure 5 ) and so inhibited the loss of memory of the events initiated during 'priming'. This will be discussed below.
Discussion
The kinetics of cell death of human CCRF CEM clone C7A lymphoid cells, induced by dexamethasone, has been defined in detail here. Although, using morphological criteria, the cells appeared to be apoptotic with high percentages of cells having an intact plasma membrane and features typical of chromatin condensation (Figure la ), we were unable to obtain good evidence of one of the cardinal biochemocal features of apoptosis, the DNA 'ladder' (Figure lb In contrast to immature mouse thymocytes treated with dexamethasone, in which the onset of apoptosis is rapid (c. 6 h) (Wyllie, 1980 ) the onset of apoptosis in clone C7A cells did not occur until after 36 h of drug exposure (Figure 2 ). During this 36 h, changes were presumably occurring that were essential for the subsequent expression of apoptosis since removal of dexamethasone at any time before this failed to induce apoptosis thereafter. This was commented on previously by Yuh & Thompson (1989) . The extended period of drug exposure, prior to the onset of changes in chromatin that heralds the death of the cell, is we suggest similar to the precommitment periods observed in cells induced to terminally differentiate after drug treatment (Yen et al., 1984; Yen 1985) . We equate this first 36 h with a period of 'priming' (Dive & Wyllie, 1993) of the cells for the subsequent second phase of the engagement of apoptosis. The separation of these two phases potentially allows for a discrete dissection of the suppression or activation of gene expression, and protein synthesis, required for apoptosis.
Evidence from transient transfection experiments, which utilised deletion constructs of the glucocorticoid receptor, suggests that transcriptional suppression is necessary for the death of clone C7A cells (Nazareth et al., 1991) . Indeed, Yuh & Thompson (1989) showed an early loss of c-myc RNA in dexamethasone-treated clone C7A cells, confirmed here at the protein level (Figure 2c ). (Mitchell et al., 1992; Beere et al., 1993a ). Thus, a key 'priming' event is not a change in cell proliferation per se, driven by a fall in c-myc expression. With respect to the idea that transcriptional repression, including that of c-nltc, is essential for the onset of apoptosis, Figure 3 shows that cycloheximide (CHX) completely inhibited apoptosis if it was present during the first 36 h of dexamethasone treatment. This is strongly suggestive of a role for new protein synthesis during the 'priming' period, presumably after transcriptional activation by the glucocorticoid, since functionally active glucocorticoid receptors are required for the death of these cells (Harmon & Thompson, 1981) . These observations suggest that activational events, including protein synthesis, were taking place, which subsequently allowed the 'machinery' of cell death to be engaged thereafter. Presumably the synthesis of new proteins, inhibited by CHX, had followed transcriptional activation by dexamethasone via a glucocorticoid-responsive element.
Incubation of CCRF CEM clone C7A cells with 200 nM CHX for 36 h also rapidly ( < 1 h) inhibited the expression of c-mnvc protein, an event suggested to be a critical harbinger of dexamethasone-induced apoptosis (Thulasi et al., 1993 ), but did not induce apoptosis, suggesting that events in addition to the loss of c-myc are critical to the engagement of apoptosis in these cells, an idea that was supported by the observation that CHX inhibited apoptosis even after the suppression of c-myc protein had occurred (> 18 h) ( Figure  3 ).
Once the cells had become 'primed', during the first 36 h of dexamethasone tretment, apoptosis then proceeded independently of new protein synthesis, since it was CHX insensitive ( Figure 3) . As the continued presence of dexamethasone was required for apoptosis during the period which followed 'priming' (i.e. after 36 h) (Figure 2) subtly, by preventing progression through some discrete 'window' of the cell cycle essential for the engagement of apoptosis. It should be noted that after 'priming' (i.e. after 36 h of dexamethasone) cells were moving out of cycle, with an accumulating number in GI phase (see Results), but were not out of cycle. Yet cycloheximide had no effect on apoptosis during the 'post-priming' period. It is possible that by 36 h all of the cells had passed through this 'window' of the cell cycle, necessary for them to later engage in apoptosis, and that cycloheximide inhibited cell death in the first 36 h by preventing passage through such a 'window'. Such a hypothesis awaits provision of populations of cell cyclesynchronised cells.
Changes which occurred in the 'priming' period, requiring protein synthesis after transcriptional activation, remained as a 'memory' during the following 36 h ( Figure 5 ). The partial maintenance of this memory by CHX ( Figure 5 ) suggests that messenger RNAs are possibly stabilised during this time. Analysis of the kinetics of changes in gene expression, and other events, during the 'priming' phase together with, and compared with, the kinetics of the decay of memory, with or without CHX, will be helpful in delineating the temporal hierarchy of events leading to the commitment to death of a cell. We plan to tackle this by a subtractive hybridisation approach (Brady et al., 1991) . It has already been commented upon that the loss of c-myc protein from CEM clone C7A cells was not an event associated with full commitment to apoptosis, since dexamethasone treatment had to be continued for at least another 24 h before the cells became committed to die and removal of dexamethasone prior to this abrogated subsequent cell death (Figure 2 and Results). This was mirrored in the kinetics of memory decay: c-myc protein was not detectable until 24 h after dexamethasone removal. Thus, from the combined data of Figures 2, 3 and 5 we suggest that it is probable that an accumulation of events before and after the suppression of c-myc expression is required before cells can become committed to die. That events before the loss of c-myc expression may be essential was suggested by the observation that as the memory of exposure to dexamethasone decayed ( Figure 5 ) cells became refractive to dexamethasone-induced apoptosis before reexpression of detectable levels of c-myc protein. Thulasi et al. (1993) recently reported that transient transfection of these cells with either inducible or constitutively expressed c-myccontaining constructs inhibited dexamethasone-induced cell death. While this supports the idea that c-myc suppression is involved in the apoptosis of these cells, our data suggest that it is certainly not sufficient for commitment of clone C7A cells to an apoptotic death.
Recent work in Rat-I fibroblasts has shown that artefactually deregulated expression of c-myc also predisposes the cells to die by apoptosis when they are grown under conditions limiting to proliferation and survival (Evan et al., 1992) . Analogous findings in myeloid and T cells have been reported (Askew et al., 1991; Shi et al., 1992) . Even et al. (1992) have suggested that, in addition to the role of c-myc in regulating cell proliferation, its capability to induce apoptosis may act as a safeguard if cell proliferation occurs independently of the appropriate growth factor signals. This idea presumes that truly deregulated expression does take place under these conditions. In support of this, earlier studies by Wyllie et al. (1987) had shown that apoptotic rates in transplanted fibroblasts were greater after transfection with the c-myc gene and the ease of induction of apoptosis in a number of different cell lines after drug treatment appeared to correlate with their expression of the c-myc gene (Bertrand et al., 1991) . However, CCRF CEM clone C7A cells do not appear to conform to this model since c-myc protein levels fell prior to the onset of apoptosis with no evidence of a rise before the onset of apoptosis. We have also recently shown that HL-60 cells, which have an amplified c-myc gene, downregulate both c-myc RNA and protein prior to apoptosis (Beere et al., 1993b) .
The kinetics of the induction of cell death, the formation of a 'memory' of exposure to dexamethasone and the kinetics of decay of this memory, modified by CHX treatment, as described here, promote the CCRF CEM clone C7A model as being valuable for further studies of the genetic changes that are required to bring about drug-induced cell death. Careful comparisons of the kinetics of dexamethasoneinduced cell death, and the associated changes in gene expression, with those of cell death induced by agents with different targets within the cell should allow the determination of the generality of the events which are necessary for the induction of cell death. Knowing these may promote strategies for the induction of cell death in chemoresistant tumours (Hickman, 1992) .
